TY - JOUR
T1 - Donor-specific antibodies in lung transplantation
AU - Hachem, Ramsey R.
N1 - Funding Information:
The current work was supported in part by NHLBI grant R34 HL138186.
Funding Information:
R.R.H. has received research grant funding from Bristol Myers Squibb and Mallinckrodt Pharmaceuticals. R.R.H. has received honoraria for advisory board memberships from Theravance Biopharma, Vecturia, and CareDx.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Purpose of reviewThe development of donor-specific antibodies (DSA) after lung transplantation has been recognized as an important risk factor for poor outcomes over the past 20 years. Recently, this has been a focus of intense research, and the purpose of this review is to summarize our current understanding of humoral responses and important recent findings as well as to identify areas of future research.Recent findingsRecent studies have identified donor-derived cell-free DNA (ddcfDNA) as an important biomarker associated with antibody-mediated rejection (AMR). Importantly, ddcfDNA levels are noted to be elevated approximately 3 months before the onset of clinical allograft dysfunction, making ddcfDNA a particularly appealing biomarker to predict the onset of AMR. Additional notable recent findings include the identification of an independent association between the isolation of Pseudomonas aeruginosa from respiratory specimens and the development of DSA. This finding provides potential insights into crosstalk between innate and alloimmune responses and identifies a potential therapeutic target to prevent the development of DSA.SummaryProgress in the field of humoral responses after lung transplantation has been slow, but ongoing and future research in this area are critically necessary to improve patient outcomes in the future.
AB - Purpose of reviewThe development of donor-specific antibodies (DSA) after lung transplantation has been recognized as an important risk factor for poor outcomes over the past 20 years. Recently, this has been a focus of intense research, and the purpose of this review is to summarize our current understanding of humoral responses and important recent findings as well as to identify areas of future research.Recent findingsRecent studies have identified donor-derived cell-free DNA (ddcfDNA) as an important biomarker associated with antibody-mediated rejection (AMR). Importantly, ddcfDNA levels are noted to be elevated approximately 3 months before the onset of clinical allograft dysfunction, making ddcfDNA a particularly appealing biomarker to predict the onset of AMR. Additional notable recent findings include the identification of an independent association between the isolation of Pseudomonas aeruginosa from respiratory specimens and the development of DSA. This finding provides potential insights into crosstalk between innate and alloimmune responses and identifies a potential therapeutic target to prevent the development of DSA.SummaryProgress in the field of humoral responses after lung transplantation has been slow, but ongoing and future research in this area are critically necessary to improve patient outcomes in the future.
KW - antibody-mediated rejection
KW - chronic lung allograft dysfunction
KW - donor-specific antibodies
KW - lung transplantation
UR - http://www.scopus.com/inward/record.url?scp=85094829422&partnerID=8YFLogxK
U2 - 10.1097/MOT.0000000000000816
DO - 10.1097/MOT.0000000000000816
M3 - Review article
C2 - 33105199
AN - SCOPUS:85094829422
SN - 1087-2418
VL - 25
SP - 563
EP - 567
JO - Current opinion in organ transplantation
JF - Current opinion in organ transplantation
IS - 6
ER -